Circulating Ceramides and Sphingomyelins and Risk of Mortality: The Cardiovascular Health Study.
Journal
Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549
Informations de publication
Date de publication:
26 11 2021
26 11 2021
Historique:
received:
23
02
2021
accepted:
17
08
2021
pubmed:
29
9
2021
medline:
14
4
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
Recent studies suggest that associations of ceramides (Cer) and sphingomyelins (SM) with health outcomes differ according to the fatty acid acylated to the sphingoid backbone. The purpose of this study was to assess associations of Cer and SM species with mortality. The study population included participants from the Cardiovascular Health Study (CHS), a community-based cohort of adults aged ≥65 years who were followed from 1992-2015 (n = 4612). Associations of plasma Cer and SM species carrying long-chain (i.e., 16:0) and very-long-chain (i.e., 20:0, 22:0, 24:0) saturated fatty acids with mortality were assessed using Cox proportional hazards models. During a median follow-up of 10.2 years, 4099 deaths occurred. High concentrations of Cer and SM carrying fatty acid 16:0 were each associated with an increased risk of mortality. Conversely, high concentrations of several ceramide and sphingomyelin species carrying longer fatty acids were each associated with a decreased risk of mortality. The hazard ratios for total mortality per 2-fold difference in each Cer and SM species were: 1.89 (95% CI), 1.65-2.17 for Cer-16, 0.79 (95% CI, 0.70-0.88) for Cer-22, 0.74 (95% CI, 0.65-0.84) for Cer-24, 2.51 (95% CI, 2.01-3.14) for SM-16, 0.68 (95% CI, 0.58-0.79) for SM-20, 0.57 (95% CI, 0.49-0.67) for SM-22, and 0.66 (0.57-0.75) for SM-24. We found no association of Cer-20 with risk of death. Associations of Cer and SM with the risk of death differ according to the length of their acylated saturated fatty acid. Future studies are needed to explore mechanisms underlying these relationships.
Sections du résumé
BACKGROUND
Recent studies suggest that associations of ceramides (Cer) and sphingomyelins (SM) with health outcomes differ according to the fatty acid acylated to the sphingoid backbone. The purpose of this study was to assess associations of Cer and SM species with mortality.
METHODS
The study population included participants from the Cardiovascular Health Study (CHS), a community-based cohort of adults aged ≥65 years who were followed from 1992-2015 (n = 4612). Associations of plasma Cer and SM species carrying long-chain (i.e., 16:0) and very-long-chain (i.e., 20:0, 22:0, 24:0) saturated fatty acids with mortality were assessed using Cox proportional hazards models.
RESULTS
During a median follow-up of 10.2 years, 4099 deaths occurred. High concentrations of Cer and SM carrying fatty acid 16:0 were each associated with an increased risk of mortality. Conversely, high concentrations of several ceramide and sphingomyelin species carrying longer fatty acids were each associated with a decreased risk of mortality. The hazard ratios for total mortality per 2-fold difference in each Cer and SM species were: 1.89 (95% CI), 1.65-2.17 for Cer-16, 0.79 (95% CI, 0.70-0.88) for Cer-22, 0.74 (95% CI, 0.65-0.84) for Cer-24, 2.51 (95% CI, 2.01-3.14) for SM-16, 0.68 (95% CI, 0.58-0.79) for SM-20, 0.57 (95% CI, 0.49-0.67) for SM-22, and 0.66 (0.57-0.75) for SM-24. We found no association of Cer-20 with risk of death.
CONCLUSIONS
Associations of Cer and SM with the risk of death differ according to the length of their acylated saturated fatty acid. Future studies are needed to explore mechanisms underlying these relationships.
Identifiants
pubmed: 34580702
pii: 6377194
doi: 10.1093/clinchem/hvab182
pmc: PMC8634404
doi:
Substances chimiques
Ceramides
0
Fatty Acids
0
Sphingomyelins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1650-1659Subventions
Organisme : NIDDK NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : National Institute of Aging
Organisme : NHLBI NIH HHS
ID : U01 HL130114
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128575
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK035816
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG023629
Pays : United States
Informations de copyright
© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Ann Epidemiol. 1991 Feb;1(3):263-76
pubmed: 1669507
Nat Rev Mol Cell Biol. 2008 Feb;9(2):112-24
pubmed: 18216768
Circ Heart Fail. 2019 Jul;12(7):e005708
pubmed: 31296099
PLoS One. 2014 Nov 21;9(11):e113605
pubmed: 25415333
J Am Heart Assoc. 2018 May 3;7(10):
pubmed: 29728014
Clin Chem. 1995 Feb;41(2):264-70
pubmed: 7874780
Lipids. 2005 Dec;40(12):1229-35
pubmed: 16477807
J Clin Endocrinol Metab. 2014 Jan;99(1):E45-52
pubmed: 24243630
FEBS Lett. 1995 Jul 3;367(3):283-6
pubmed: 7607324
Eur J Prev Cardiol. 2022 May 6;29(6):895-902
pubmed: 33624052
J Clin Invest. 1996 May 1;97(9):2081-91
pubmed: 8621798
Stat Methods Med Res. 1999 Mar;8(1):3-15
pubmed: 10347857
Am J Clin Nutr. 1994 Dec;60(6 Suppl):1029S-1036S
pubmed: 7977145
Cell Metab. 2012 May 2;15(5):585-94
pubmed: 22560211
Obesity (Silver Spring). 2011 Nov;19(11):2235-40
pubmed: 21546935
Cell Metab. 2018 Feb 6;27(2):276-280
pubmed: 29307517
Science. 2008 Oct 3;322(5898):110-5
pubmed: 18832646
Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2424-2430
pubmed: 27765765
Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R11-26
pubmed: 16352856
Eur Heart J. 2016 Jul 01;37(25):1967-76
pubmed: 27125947
Adv Exp Med Biol. 2011;721:41-56
pubmed: 21910081
Ann Epidemiol. 1995 Jul;5(4):278-85
pubmed: 8520709
Adv Exp Med Biol. 2011;721:19-39
pubmed: 21910080
Prog Lipid Res. 2006 Jan;45(1):42-72
pubmed: 16445986
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
J Nutr. 2003 Apr;133(4):1060-3
pubmed: 12672919
Mech Ageing Dev. 2014 Dec 15;143-144:9-18
pubmed: 25437839
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1933-1939
pubmed: 29903731
PLoS Genet. 2012 Feb;8(2):e1002493
pubmed: 22319457
J Lipid Res. 2018 Sep;59(9):1729-1737
pubmed: 29858423
J Nutr. 2015 Apr 1;146(4):662-672
pubmed: 26962194
Proc Soc Exp Biol Med. 2000 Dec;225(3):191-9
pubmed: 11082213
Lipids Health Dis. 2013 Jul 08;12:98
pubmed: 23835113
Atherosclerosis. 2013 Jan;226(1):16-28
pubmed: 23075523
Eur Heart J. 2020 Jan 14;41(3):371-380
pubmed: 31209498
Am J Clin Nutr. 1999 Dec;70(6):1001-8
pubmed: 10584044
JCI Insight. 2018 Sep 6;3(17):
pubmed: 30185661
Prog Lipid Res. 2012 Jan;51(1):50-62
pubmed: 22133871
Expert Opin Ther Targets. 2011 Sep;15(9):1061-71
pubmed: 21635197
Metabolism. 1999 Dec;48(12):1485-92
pubmed: 10599977
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2498-502
pubmed: 9482914
J Am Heart Assoc. 2020 Feb 18;9(4):e012853
pubmed: 32019406
Atherosclerosis. 2015 Dec;243(2):560-6
pubmed: 26523994
Diabetes. 2018 Aug;67(8):1663-1672
pubmed: 29588286
J Clin Invest. 2018 Jul 2;128(7):2702-2712
pubmed: 30108193
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2614-8
pubmed: 11116061